Harvard Bioscience (HBIO) Stock Statistics & Valuation Metrics

Harvard Bioscience has a market cap or net worth of $26.68M. The enterprise value is $62.49M.

Harvard Bioscience has 44,719,894 shares outstanding. The number of shares has decreased by -2.65% in one year.

Harvard Bioscience’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -5.66%.

The current PE Ratio of Harvard Bioscience is ―. Harvard Bioscience’s PEG ratio is -0.03.

In the last 12 months, Harvard Bioscience had revenue of 94.14M and earned -12.40M in profits. Earnings per share was -0.28.

In the last 12 months, operating cash flow was 8.30M and capital expenditures -1.42M, giving a free cash flow of 6.88M billion.

Harvard Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Harvard Bioscience upcoming earnings date is Mar 12, 2026, After Close (Confirmed).

Harvard Bioscience as a current ratio of 0.82, with Debt / Equity ratio of 304.13%

In the past 12 months, Harvard Bioscience has paid 740.00K in taxes.

Harvard Bioscience EV to EBITDA ratio is -89.72, with an EV/FCF ratio of -72.55.

Harvard Bioscience has $6.82M in cash and marketable securities with $42.78M in debt, giving a net cash position of -$35.97M billion.

Gross margin is 55.61%, with operating margin of -6.60%, and net profit margin of -13.18%.

The average price target for Harvard Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―